PF-AtlasClinical Trials › NCT06698783

Practical Application and Evaluation of Fortimel in Oncology Patients

Fortimel · Not specified

Registry ID
NCT06698783
Phase
Not specified
Status
Not yet recruiting
Drug / intervention
Fortimel
Sponsor
Peking Union Medical College Hospital
Start
2024-12-01
Enrollment
2000
Locations
1

About this trial

This study is a multicenter registry and is a prospective, observational, real-world study. Subjects were selected by clinicians for oral ONS nutritional intervention according to the actual clinical situation and the patient's wishes, and the observation period was 4 weeks. Subjects will receive a ready-to-drink marketed formula for special medical purposes with 4 flavors for free Food liquid preparation (Nengli Yijia, Nutricia in the Netherlands) for rounds of nutritional intervention, providing 1 flavor per week, 1-2 bottles per day, 4 flavors for a total of 28 days. The basic nutritional status and quality of life of patients were mainly evaluated at multiple time nodes before and after nutritional intervention. In order to improve the compliance of subjects, the all-round guardian platform (hereinafter referred to as the platform) by the China Initial Insurance Foundation was used during the intervention period to provide basic nutrition supervision, education and dietary guidance in routine nutrition support. Recruitment method: Convenient sampling method is adopted, from the beginning of recruitment to the target sample size. Follow-up period: After the start of the intervention, it will be carried out according to the plan of the follow-up task to the end of the intervention on the 28th day. The last telephone follow-up visit will complete on the 60th day after the end of the pre-end.

View NCT06698783 on ClinicalTrials.gov →

Explore related

Medical disclaimer. This page summarizes public trial data for NCT06698783 for information only. It is not medical advice, an endorsement, or an offer to enroll. Confirm details on ClinicalTrials.gov and with a qualified physician.